首页> 外文期刊>Journal of Clinical Pathology >Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus
【24h】

Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus

机译:食管局部晚期鳞状细胞癌中p53和bcl-2的表达及其对术前化疗和放疗的反应

获取原文
获取原文并翻译 | 示例
           

摘要

Aims—To investigate the immunohistochemical expression of p53 and bcl-2 proteins in squamous cell carcinoma (SCC) of the oesophagus and to assess whether expression of these oncoproteins can be used to stratify patients into groups with a favourable or unfavourable response to preoperative chemo/radiotherapy. Methods—The initial diagnostic biopsy and the corresponding resected samples were obtained from 22 consecutive patients with SCC. All patients underwent preoperative chemo/radiotherapy. Tumour sections were incubated with a monoclonal antibody directed against p53 (DO-7). Twenty four non-neoplastic oesophageal biopsy specimens immunostained for p53 served as controls. Twelve randomly chosen sections from the 22 SCC samples were immunostained to test for bcl-2 protein expression. Results—After chemo/radiotherapy, 12 (55%) of the 22 patients had no evidence of tumour in the resected oesophagus. Before chemoradiotherapy, however, 17 (77%) patients were p53 positive. After treatment, residual carcinoma was detected in seven (41%) of the 17 p53 positive patients. All non-responsive cases had the same p53 immunopattern as before treatment. Bcl-2 immunoexpression was detected in six (50%) of 12 patients. Residual tumour was detected in the residual oesophagus in two (33%) of the six bcl-2 positive patients. After treatment, bcl-2 expression was no longer detected in the residual neoplastic cells of a previously bcl-2 positive tumour. Using Fisher's exact test no significant association was found between oncoprotein expression and response to preoperative treatment. Conclusion—This study confirms the observation that p53 protein is frequently expressed in SCCs of the oesophagus, probably as a result of a mutation of the TP53 gene. However, no significant association was found between oncoprotein expression and response to chemo/ radiotherapy. Anticancer agents do not seem to modify the expression of p53 and bcl-2 proteins.
机译:目的—研究p53和bcl-2蛋白在食道鳞状细胞癌(SCC)中的免疫组织化学表达,并评估这些癌蛋白的表达是否可用于将患者分为对术前化学/化学反应良好或不利的人群放疗。方法-最初的诊断性活检和相应的切除标本取自连续22例SCC患者。所有患者均接受术前化学/放射治疗。肿瘤切片与针对p53的单克隆抗体(DO-7)孵育。对p53免疫染色的二十四个非肿瘤性食管活检标本用作对照。从22个SCC样本中随机选择12个切片进行免疫染色以测试bcl-2蛋白的表达。结果—化学/放射治疗后,在22例患者中有12例(55%)在切除的食管中没有肿瘤的迹象。然而,在放化疗之前,有17名(77%)患者为p53阳性。治疗后,在17例p53阳性患者中有7例(41%)检测到残留癌。所有无反应的病例均具有与治疗前相同的p53免疫模式。在12例患者中有6例(50%)检测到Bcl-2免疫表达。 6名bcl-2阳性患者中有2名(33%)在残留的食道中发现了残留的肿瘤。治疗后,在以前的bcl-2阳性肿瘤的残留肿瘤细胞中不再检测到bcl-2表达。使用Fisher精确检验,未发现癌蛋白表达与术前治疗反应之间存在显着关联。结论—这项研究证实了以下观察结果:p53蛋白经常在食管的SCC中表达,可能是TP53基因突变的结果。然而,癌蛋白表达与化学/放射治疗反应之间没有显着关联。抗癌药似乎并未改变p53和bcl-2蛋白的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号